Moody Aldrich Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Moody Aldrich Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-47,035	Closed	-$2.28M	–	154
2020 Q2	$2.28M	Sell	47,035 -73,181	-61%	-$3.51M	0.48%	78
2020 Q1	$5.08M	Sell	120,216 -170	-0.1%	-$7K	1.53%	18
2019 Q4	$5.15M	Buy	120,386 +23,147	+24%	+$1.01M	1.06%	29
2019 Q3	$3.5M	Buy	97,239 +63,493	+188%	+$1.93M	0.93%	45
2019 Q2	$902K	Sell	33,746 -26,263	-44%	-$671K	0.23%	90
2019 Q1	$1.61M	Sell	60,009 -38,797	-39%	-$906K	0.45%	84
2018 Q4	$1.6M	Buy	98,806 +5,921	+6%	+$115K	0.52%	73
2018 Q3	$1.93M	Buy	+92,885	New	+$1.46M	0.56%	79
2018 Q1	–	Sell	-35,701	Closed	-$1.07M	–	87
2017 Q4	$1.07M	Buy	35,701 +6,782	+23%	+$217K	0.87%	56
2017 Q3	$1.09M	Buy	28,919 +10,304	+55%	+$335K	1.12%	42
2017 Q2	$519K	Buy	+18,615	New	+$555K	0.65%	75
2016 Q4	–	Sell	-19,110	Closed	-$608K	–	89
2016 Q3	$608K	Buy	+19,110	New	+$648K	0.42%	90

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Moody Aldrich Partners's ACAD Position: Q3 2020 in Review

Moody Aldrich Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 47,035 shares — an estimated $2.28M sold.

Moody Aldrich Partners first reported a position in ACAD in Q3 2016 and held it in 12 quarters. The position peaked at $5.15M in Q4 2019. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Moody Aldrich Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Moody Aldrich Partners sold 47,035 Acadia Pharmaceuticals shares in Q3 2020, an estimated $2.28M.
Moody Aldrich Partners first reported a position in Acadia Pharmaceuticals in Q3 2016 and held it in 12 quarters.
Moody Aldrich Partners's Acadia Pharmaceuticals position peaked at $5.15M in Q4 2019.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Moody Aldrich Partners's 13F filing for Q3 2020, filed 12 Nov 2020.